Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Esperion. The associated price target remains the same with $16.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Joseph Pantginis has given his Buy rating due to a combination of factors including Esperion’s strong financial performance and strategic initiatives. The company reported better-than-expected earnings for the second quarter of 2025, with an EPS of ($0.02) compared to the estimated ($0.18), and a significant increase in U.S. product revenue for NEXLETOL/NEXLIZET. This growth is attributed to a rise in retail prescriptions and increased adoption among the statin intolerant community.
Esperion’s efforts to expand globally and enhance its market presence also contribute to the positive outlook. The company has achieved approval for its BDA product in 40 countries, with further approvals anticipated in Japan, Canada, Israel, and Australia. Additionally, strategic partnerships, such as with Daiichi Sankyo, have bolstered revenue and patient reach. Esperion’s commitment to advancing its ACLYi development portfolio and targeting new therapeutic areas further supports the Buy rating, as these initiatives are expected to drive future value creation.